Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.53 |
| ▸ | MAOB | P27338 | 3/20 | 0.53 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 3/20 | 0.48 |
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | CA9 | Q16790 | 3/20 | 0.48 |
| ▸ | BCL2 | P10415 | 2/20 | 0.47 |
| ▸ | KIF11 | P52732 | 1/20 | 0.44 |
| ▸ | RNF114 | Q9Y508 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15987950 | 0.86 | PRKCZ (0.55) | MAOAMAOBPRKCZCA12CA1 | |
| SCHEMBL5058846 | 0.81 | L3MBTL1 (0.59) | MAOAMAOBL3MBTL1KDM4E | |
| SCHEMBL17554565 | 0.78 | MAOA (0.58) | MAOAMAOBPRKCZCA12CA1 | |
| SCHEMBL25274761 | 0.76 | KIF11 (0.53) | MAOAMAOBPRKCZCA12CA1 | |
| SCHEMBL26508543 | 0.72 | KDM4E (0.52) | MAOAMAOBCA12CA1CA2 | |
| SCHEMBL16088364 | 0.69 | TSHR (0.57) | KDM4E | |
| SCHEMBL18918345 | 0.66 | LMNA (0.54) | L3MBTL1KDM4E | |
| SCHEMBL27936553 | 0.65 | CACNA1H (0.64) | MAOAMAOBRNF114ACHEKDM4E | |
| SCHEMBL17504154 | 0.65 | LMNA (0.50) | L3MBTL1 | |
| SCHEMBL26508522 | 0.65 | SMN1; SMN2 (0.45) | L3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522914-B2 | Azole derivative | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2016-12-20 | — | — | US | disclosed |
| US-9522914-B2 | Azole derivative | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2016-12-20 | — | — | US | disclosed |
| US-20140275006-A1 | AZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2014-09-18 | — | — | US | disclosed |
| US-20140275006-A1 | AZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275006-A1 | AZOLE DERIVATIVE | AVPR1B, AVPR1A, AVPR2 | MAOA 496/4885MAOB 145/4885PRKCZ 2136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.